Posted by Michael Wonder on 05 Dec 2018
Johnson & Johnson CEO says fix the drug pricing process, but not too much
4 December 2018 - When it comes to drug pricing, Johnson & Johnson’s CEO says he’s open to change. But he is also quick to defend the importance of how breakthrough drugs are improving patient’s lives.
That, he says, justifies high prices.
CEO Alex Gorsky tells Fortune, “Obviously you’ve got to work with payers, providers. You’ve got to work with the government to make sure that’s done in a responsible way.” But he warns, “I think we need to be thoughtful about is making wholesale changes to the system that could have untoward consequences that ultimately restricts patients access to those kinds of products or actually is a disincentive to continue research that’s going to produce that next breakthrough.”
